(Q43548171)

24 November 2017

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. (English)

1 reference

24 November 2017

R Soni

1

1 reference

24 November 2017

T O'Reilly

2

1 reference

24 November 2017

P Furet

3

1 reference

24 November 2017

L Muller

4

1 reference

24 November 2017

C Stephan

5

1 reference

24 November 2017

S Zumstein-Mecker

6

1 reference

24 November 2017

H Fretz

7

1 reference

24 November 2017

D Fabbro

8

1 reference

24 November 2017

B Chaudhuri

9

1 reference

24 November 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

Journal of the National Cancer Institute

24 November 2017

1 reference

24 November 2017

93

1 reference

24 November 2017

436-446

1 reference

24 November 2017

6

1 reference

Four-dimensional control of the cell cycle

24 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Inhibitors of mammalian G1 cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

The retinoblastoma protein pathway and the restriction point

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

The retinoblastoma protein and cell cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

The regulation of E2F by pRB-family proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Mutations and altered expression of p16INK4 in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Growth suppression by p16ink4 requires functional retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

DNA binding protein dbpA binds Cdk5 and inhibits its activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

D-type cyclin-dependent kinase activity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Inhibition of cyclin-dependent kinases by p21

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Assay for activity of mammalian cyclin D-dependent kinases CDK4 and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Simulation of protein-sugar interactions: a computational model of the complex between ganglioside GM1 and the heat-labile enterotoxin of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Evidence for an early G1 ionic event necessary for cell cycle progression and survival in the MCF-7 human breast carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Requirement for tyrosine phosphorylation of Cdk4 in G1 arrest induced by ultraviolet irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Cell cycle start from quiescence controlled by tyrosine phosphorylation of Cdk4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

A biomarker that identifies senescent human cells in culture and in aging skin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Regulation of exit from quiescence by p27 and cyclin D1-CDK4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

The effects of transferring tumor suppressor gene p16INK4A to p16INK4A-deleted cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Characterization of novel inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Overexpression of cyclin D1 and cdk4 in tumorigenesis of sporadic hepatoblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F93.6.436

21 January 2018

Identifiers

DOI

10.1093/JNCI/93.6.436

1 reference

24 November 2017

1 reference